The 3P-C Trial (Intraductal Papillary Mucinous Neoplasms) - Clinical Trial

If you choose to join this study, you will:
- Be randomized to Group 1 or Group 2
-- Group 1 will get the study drug (Sulindac)
-- Group 2 will get a placebo (harmless sugar pill)

Both groups will have:
- CT scans (body scan)
- Endoscopy's (a way to look at your digestive tract)
- Collection of cyst fluid from the pancreas

Intraductal Papillary Mucinous Neoplasms (IPMN)

- Men and women 21-85 years old
- Diagnosed with high-risk intraductal papillary mucinous neopolasm (IPMN)

We are doing this study to learn more about how the study drug, Sulindac, effects people with high risk intraductal papillary mucinous neoplasms (IPMN). The study drug (Sulindac) is a non-steroidal, anti-inflammatory medicine commonly called an NSAID.